Absence of PD-L1 signaling hinders macrophage defense against Mycobacterium tuberculosis via upregulating STAT3/IL-6 pathway

Peijie Qu,Xinyu Li,Weihuang Liu,Fangting Zhou,Xiaoxu Xu,Jun Tang,Mengmeng Sun,Junli Li,Haifeng Li,Yunlin Han,Chengjun Hu,Yueshan Lei,Qin Pan,Lingjun Zhan
DOI: https://doi.org/10.1016/j.micinf.2024.105352
IF: 9.57
2024-05-09
Microbes and Infection
Abstract:The blockade of programmed death-ligand 1 (PD-L1) pathway has been clinically used in cancer immunotherapy, while its effects on infectious diseases remain elusive. Roles of PD-L1 signaling in the macrophage-mediated innate immune defense against M.tb is unclear. In this study, the outcomes of tuberculosis (TB) in wild-type (WT) mice treated with anti-PD-1/PD-L1 therapy and macrophage-specific Pdl1 -knockout ( Pdl1 ΔΜΦ ) mice were compared. Treatment with anti-PD-L1 or anti-PD-1 benefited protection against M.tb infection in WT mice, while Pdl1 ΔΜΦ mice exhibited the increased susceptibility to M.tb infection. Mechanistically, the absence of PD-L1 signaling impaired M.tb killing by macrophages. Furthermore, elevated STAT3 activation was found in PD-L1-deficient macrophages, leading to increased interleukin (IL)-6 production and reduced inducible nitric oxide synthase (iNOS) expression. Inhibiting STAT3 phosphorylation partially impeded the increase in IL-6 production and restored iNOS expression in these PD-L1-deficient cells. These findings provide valuable insights into the complexity and mechanisms underlying anti-PD-L1 therapy in the context of tuberculosis.
immunology,infectious diseases,microbiology
What problem does this paper attempt to address?